Antigen-driven immune tolerance

Antigen-driven immune tolerance is a physiological state of active non-responsiveness to specific antigens, serving as a critical mechanism for maintaining self-tolerance and preventing overreactions to environmental stimuli (Nature Reviews Immunology, 2020). Unlike broad immunosuppression, this process is antigen-specific, aiming to reprogram the immune system to ignore particular triggers while leaving general immunity intact. In clinical practice, this is achieved through antigen-specific immunotherapy (ASIT), where controlled exposure to an antigen induces the expansion of regulatory T cells (Tregs) and the production of anti-inflammatory cytokines (Journal of Clinical Investigation, 2019). This approach is widely used in the treatment of allergic diseases, such as hay fever and food allergies, and is a major area of research for autoimmune conditions like multiple sclerosis and type 1 diabetes. Because it involves a complex orchestration of various immune cells and signaling pathways rather than a single protein, it is characterized as a system-level therapeutic strategy without a defined molecular receptor (Frontiers in Immunology, 2021). Consequently, drug development in this space focuses on delivery platforms and adjuvants that can reliably induce this tolerogenic state.

Other names

Antigen-specific toleranceImmune tolerance inductionPeripheral toleranceDesensitizationAntigen-specific immunotherapy

The mechanism involves the presentation of specific antigens by tolerogenic dendritic cells to naive T cells, leading to the differentiation of regulatory T cells (Tregs) that secrete suppressive cytokines like IL-10 and TGF-beta (Nature Reviews Immunology, 2020). This process results in the functional inactivation (anergy) or physical removal (deletion) of self-reactive or allergen-specific effector T cells, thereby restoring immune homeostasis (Frontiers in Immunology, 2021).